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Abstract
Background: Before their diagnosis, patients with cancer present in primary care more
frequently than do matched controls. This has raised hopes that earlier investigation in
primary care could lead to earlier stage at diagnosis.
Methods: We re-analysed primary care symptom data collected from 247 lung cancer
cases and 1235 matched controls in Devon, UK. We identified the most sensitive and
specific definition of symptoms, and estimated its incidence in cases and controls prior
to diagnosis. We estimated the symptom lead time (SLT) distribution (the time between
symptoms attributable to cancer and diagnosis), taking account of the investigations al-
ready carried out in primary care. The impact of route of diagnosis on stage at diagnosis
was also examined.
Results: Symptom incidence in cases was higher than in controls 2 years before diagno-
sis, accelerating markedly in the last 6 months. The median SLT was under 3 months,
with mean 5.3 months [95% credible interval (CrI) 4.5–6.1] and did not differ by stage at
diagnosis. An earlier stage at diagnosis was observed in patients identified through chest
X-ray originated in primary care.
Conclusions: Most symptoms preceded clinical diagnosis by only a few months.
Symptom-based investigation would lengthen lead times and result in earlier stage at
diagnosis in a small proportion of cases, but would be far less effective than standard
screening targeted at smokers.
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There has been increasing emphasis on the need for earlier
investigation of suspected cancer in primary care. In the 2
years before diagnosis, individuals with lung cancer pre-
sent more frequently in primary care than do matched con-
trols with cancer-related symptoms.1–3 Similar findings
have been reported for colorectal,4 ovarian5,6 and other
cancers.4 These studies have given rise to optimism that
earlier diagnosis could be achieved by instituting explicit
criteria for investigation in primary care.7 In the UK, the
Department of Health launched early awareness cam-
paigns in 2011, advising individuals with particular symp-
toms to attend their general practitioner (GP) surgery.8 In
several countries, including England, Wales, Scotland and
Denmark, guidance recommends urgent cancer investiga-
tion in certain scenarios.
However, information on the predictive value and rela-
tive frequency of symptoms in cases and controls1–5 does
not allow one to quantify how much earlier diagnosis
could be made if criteria for investigation were changed,
nor how many cancers currently diagnosed at a late stage
could be diagnosed at an earlier stage, when better treat-
ment options exist. This study shows how this information
can be derived and presents results for lung cancer. The
same methods can be applied to other cancers, to provide
insights into natural history before diagnosis, and to assess
the role of symptom-based investigation.
The target parameter is the symptom lead time distribu-
tion (SLT), defined here as the interval between the occur-
rence of a particular symptom, or set of symptoms,
attributable to cancer and the eventual diagnosis of cancer
if no further action is taken. Some diagnoses of lung cancer
are already the direct result of symptom presentation in
primary care, because GPs already investigate by chest
X-ray (CXR) on the basis of symptoms. In these patients, if
no CXR had been requested, the date of diagnosis would
have been later, and the SLT longer. This needs to be con-
sidered when estimating the SLT.
An investigational strategy based on symptoms present-
ing in primary care may lead to earlier diagnosis and better
outcomes. However, the sensitivity and specificity of these
symptoms may approximate the sensitivity and specificity
of smoking as a marker of lung cancer risk. We compare
symptom-based and smoking-based investigational strat-
egies in the light of our results.
Methods
This paper presents a new analysis of the Cancer
Prediction in Exeter (CAPER) study.1 Data was collected
on 247 lung cancer cases diagnosed in Exeter, England,
1998–2002, and 1235 age-, sex- and practice-matched
controls. GP attendances and symptoms were recorded
over the 2 years before the case was diagnosed. The cancer
stage notation (TNM) at diagnosis was available from the
local cancer registry, supplemented by searches of the pri-
mary care records where necessary. CXRs ordered by the
GP, classified as ‘normal, ‘abnormal’ and ‘suspected lung
cancer’ were also recorded,9 as were emergency admissions
that led to a diagnosis of lung cancer.
Symptoms
We examined attendances for cough, dyspnoea, chest pain,
fatigue, loss of weight, loss of appetite and haemoptysis.
From these we derived several sets of potential criteria for
investigation by appropriate imaging. These were: (i)
cough; (ii) dyspnoea; (iii) chest pain; (iv) fatigue, loss of
weight, loss of appetite or haemoptysis; and (v) any of
these seven symptoms. We also explored (vi) any two
symptoms, including repeat attendances with the same
symptom, presenting within 1, 2, 3, 4, 5 or 6 months, and
(vii) the same six variants but excluding repeats of the
same symptom. We used receiver operating characteristic
(ROC) plots,10 to assess the ability of symptom criteria to
discriminate between cases and controls.
Symptom incidence and symptom lead time
distribution
We estimated the rate of symptom presentation in cases
and controls during each quarter year before diagnosis
Key Messages
• Individuals with undiagnosed lung cancer attend general practice with suggestive but non-specific symptoms more often
than matched controls, but the great majority of the excess attendances precede the diagnosis date by a only few months.
• As a result, a strategy of diagnostic imaging of patients with such symptoms will bring forward diagnosis, and will
lead to earlier stage diagnosis, but the effects will be modest.
• A standard screening programme for smokers would be likely to have much greater benefits for those diagnosed, in
terms of lead time and the proportion diagnosed at an early stage.
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via Poisson regression, and interpreted the difference be-
tween cases and controls in quarter T as the rate attrib-
utable to lung cancer. The SLT distribution is given by
the ratio of the cancer-related incidence of symptoms in
quarter T to the sum of cancer-related incidence across
all quarters. We also examined the proportion of all
symptoms that were cancer-related, estimated as the in-
cidence of symptoms in cases minus incidence in
matched controls, divided by the incidence in cases. A
Bayesian Markov chain Monte Carlo analysis was
adopted, as it allows flexibility to estimate non-standard
models. Full details of the statistical model with an ex-
ample dataset and annotated programming code are
provided as appendices available in Supplementary data
at IJE online.
SLT was estimated in (i) the full dataset and (ii) exclud-
ing cases who had a ‘suspected lung cancer’ finding on
CXR in the 4 months before diagnosis, and who were not
admitted as an emergency. These provided minimum and
maximum estimates of SLT, respectively, as explained
below.
Ethics approval
Ethical approval for the original study was given by the
North and East Devon research ethics committee.
Results
Stage at diagnosis
Of the 247 cases, 113 (45.7%) were reported as unknown
stage at diagnosis. These were combined with the 55 diag-
nosed as Stage 4. On this basis, the proportions in Stages 1,
2, 3 and 4 are therefore 12.6%, 6.9%, 12.6% and 68%,
respectively.
Ability of alternative criteria to discriminate
cases and controls
Table 1 shows the proportion of cases and controls who
ever presented with each symptom combination over the 2-
year period. As previously reported,1–3 symptoms vary in
their sensitivity and specificity for lung cancer: isolated
cough picks up over half the cases, but would also lead to
investigations in 29.5% of controls. Haemoptysis is highly
specific (present in only 1.5% of controls), but would iden-
tify only 20% of cases. At the other extreme, ‘any symp-
tom’ is very sensitive (91.9%) but also very non-specific
(47%) (Figure 1).
‘Any two symptoms within 3 months’ was the most
discriminating criterion, based on the Youden Index (sensi-
tivityþspecificity-1) (Table 1), with 80.6% sensitivity and
23.2% false positives. All analyses reported below are based
Table 1. Percentage of cases and controls who ever presented with symptoms meeting investigative criteria during the 2 years
















Cough 54.8 64.7 61.3 67.3 64.8 29.5 35.3 (29–49)
Dyspnoea 38.7 41.2 64.5 59.5 56.3 15.5 40.7 (34–47)
Chest pain 35.5 47.1 38.7 41.1 40.5 12.1 28.3 (22–35)
Fatigue 41.9 11.8 35.5 36.3 35.2 15.1 20.2 (14–26)
Loss of weight 12.9 41.2 22.6 29.2 27.1 4.4 22.8 (17–28)
Loss of appetite 12.9 17.6 25.8 19.0 19.0 4.0 15.1 (10–20)
Haemoptysis 29.0 29.4 12.9 19.0 20.2 1.5 18.7 (14–24)
Fatigue, loss of weight or appetite, haemoptysis 67.7 58.8 61.3 65.5 64.8 20.4 44.4 (38–51)
Any symptom 90.3 88.2 93.5 92.3 91.9 47.2 44.7 (40–49)
Two symptoms in 1 month 67.7 76.5 80.6 76.8 76.1 20.5 55.6 (50–61)
Two symptoms in 2 months 71.0 82.4 80.6 78.6 78.1 22.3 55.8 (50–61)
Two symptoms in 3 months 74.2 82.4 83.9 81.0 80.6 23.2 57.4 (52–63)
Two symptoms in 4 months 74.2 82.4 83.9 81.0 80.6 23.7 56.8 (51–62)
Two symptoms in 5 months 77.4 82.4 83.9 82.1 81.8 24.8 57.0 (52–62)
Two symptoms in 6 months 80.6 82.4 83.9 82.1 82.2 25.4 56.8 (51–62)
Two different symptoms in 1months 61.3 70.6 74.2 70.8 70.0 15.4 54.7 (49–61)
Two different symptoms in 2months 64.5 76.5 77.4 73.2 72.9 16.5 56.4 (50–62)
Two different symptoms in 3months 67.7 76.5 80.6 73.8 74.1 17.0 57.1 (51–63)
Two different symptoms in 4months 67.7 76.5 80.6 73.8 74.1 17.9 56.2 (50–62)
Two different symptoms in 5months 71.0 76.5 80.6 74.4 74.9 18.5 56.4 (51–62)
Two different symptoms in 6months 74.2 76.5 80.6 75.6 76.1 19.0 57.1 (51–63)
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on this symptom criterion. Criteria based on two different
symptoms lie on a similar ROC curve, with both the sensi-
tivity and the false-positive rate reduced by 4–6% compared
with criteria including repeat attendances with the same
symptom. The prevalence of symptoms before diagnosis
was not strongly correlated with stage at diagnosis.
GP referrals for CXR
In total 167 (67.7%) of cases and 101 (8.2%) of controls
were referred for CXR by their GP. Nearly every finding of
‘suspected lung cancer’ was associated with a diagnosis
within 4 months (Table 2). However, only 51 of 89 (57%)
‘abnormal, but not suspicious of cancer’ CXR findings
occurred within 4 months of diagnosis. In Table 3 we have
grouped together as ‘diagnosis not influenced by CXR’ all
those who either had no ‘suspected lung cancer’ or ‘abnor-
mal’ CXR finding in the 4 months before diagnosis or
who, regardless of CXR findings, had an emergency admis-
sion. These are, in effect, the cases whose date of diagnosis
has not been materially brought forward by a CXR. Those
with ‘suspected lung cancer CXR’ in the last 4 months had
a symptom rate over the first 20 months of 0.21 per year,
similar to the symptom rate in controls of 0.18. In contrast,
those with an ‘abnormal but not suspicious of cancer’
CXR in the last 4 months have a symptom rate in months
1–20 (0.51) that is indistinguishable from the symptom
rate in the ‘diagnosis not influenced by CXR’ cases (0.54).
The two groups were therefore combined.
Estimates of incidence and symptom
lead time distribution
For all stages, the incidence of symptoms in cases rises from
a level slightly higher than in controls, and accelerates
rapidly in the 6 months before diagnosis (Figure 2). SLT
was estimated in two datasets, first in the full dataset, and
second in a dataset excluding those with a ‘suspected lung
cancer’ CXR finding in the 4 months before diagnosis and
no emergency admission. Figure 3 shows the three sets of
SLTs for each stage: the minimum SLT, based on the entire
dataset; the maximum SLT, based on the second dataset;
and our preferred estimate of SLT, which is halfway be-
tween. The differences between the minimum and
Figure 1. Sensitivity and specificity of symptom definitions in the
CAPER study. Co, cough; m, months; Dy, dyspnoea; Cp, chest pain; Fþ,
fatigue, loss of weight, loss of appetite, or haemoptysis; Any, any of the
seven symptoms; nm, any two symptoms in n months; dnm, any two
different symptoms in nmonths.
Table 2. Numbers (rates x 100) of CXRs, and person-years at risk (PYARs), in cases and controls: timing and results
Patients Interval, months N PYAR ‘Abnormal’ CXR ‘Suspected lung cancer’ CXR
Cases 1–20 247 411.7 38 (9.2) 2 (0.49)
Cases 21–24 247 8.23 51 (620) 101 (1227)
Controls 1–24 1235 2470 41 (1.66) 3 (0.12)
Table 3. Numbers of times the symptom criterion ‘any 2 symptoms in 3 months’ was met, and the rates; estimates as events div-
ided by person-years at risk (PYARs), in cases and controls, by CXR findings in the last 4 months before diagnosis
Patients Interval, months Number of patients PYAR Number of events (rates, per year)
Cases, CXR ‘abnormal’ 1–20 29 48.3 25 (0.51)
21–24 29 7.25 37 (3.8)
Cases, CXR ‘suspected lung cancer’ 1–20 92 153 33 (0.21)
21–24 92 3.1 85 (2.75)
Cases ‘diagnosis not influenced by CXR’ 1–20 126 210 115 (0.54)
21–24 126 42 91 (2.15)
Controls 1–24 1235 2470 438 (0.18)
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maximum results are relatively narrow. Mean SLTs by
stage at diagnosis are shown in Figure 4. The average SLTs,
weighted in proportion to the sample stage distribution, are
4.8 months (minimum estimate), 5.7 months (maximum)
and 5.3 months [95% CrI: 4.5–6.1] as the intermediate esti-
mate. These figures represent the SLT of symptoms attrib-
utable to lung cancer in the 81 % of cases who met the
criterion ‘any two symptoms within the same 3 months’.
Symptoms attributable to lung cancer comprised 79%
[95% CrI: 76%–82%] of all symptoms in the 2 years be-
fore diagnosis. Overall, 52% of cases had SLTs of 3 months
or less, suggesting a median SLT of just under 3 months.
Very similar SLT distributions were found for other in-
vestigative criteria, such as cough, any symptom and ‘any
Figure 2. Incidence of ‘any two symptoms in 3 months’ in cases and controls. Blue lines represent cases, dashed blue lines are 95% credible intervals,
red lines are controls.
Figure 3. Symptom lead time distribution, ‘any two symptoms in 3 months’. Red line represents full dataset, green line excludes ‘suspected lung can-
cer’ CXR findings in the last 4 months, blue line intermediate or average, dashed blue lines 95% credible intervals.
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two different symptoms in 3 months’. Incidence and
SLT plots are shown in the appendices available in
Supplementary data at IJE online.
Discussion
This paper joins a series of reports of higher risks of early
symptom presentation in cancer cases compared with
matched controls,1–5 which have given rise to optimism
that cancers could be diagnosed earlier, and at an earlier
stage, if symptom-based criteria for immediate investigation
were adopted in primary care. In the UK, the Department
of Health has advocated Early Awareness campaigns (see:
http://www.nhs.uk/be-clear-on-cancer/Pages/beclearoncancer.
aspx), encouraging patients with symptoms, such as
persistent cough for lung cancer, or haematuria for bladder
cancer, to attend general practice.8 The lung cancer cam-
paign has been reported as increasing GP attendance rates
for cough symptoms, the number of cancers diagnosed and
the proportion diagnosed at an early stage.11
Symptom rates and CXR rates in the study on which
the present analysis is based accord with much earlier
larger studies.2,3 An ideal symptom-based strategy would
be based on symptom criteria that are both sensitive and
specific markers of lung cancer. Our results suggest that
isolated symptoms are inferior to pairs of symptoms or re-
peat symptoms. The most discriminating criterion was any
two symptoms presenting within 3 months. In the 2-year
study window, this identified 81% of cases and 23% of
controls. In the UK, the Be Clear on Cancer Campaign uses
a criterion of persistent cough,11 which is less sensitive and
less specific. Current National Institute for Health and
Care Excellence (NICE) guidance7 lists only single symp-
toms, without reference to paired or multiple symptoms,
although the clinician is expected to exercise judgment.
Similar guidelines exist in Scotland. In Denmark, criteria
for investigation are entirely at GPs’ discretion.
Much larger studies have shown that sensitivity and
specificity of investigative criteria can be improved by add-
ing smoking, age, chronic obstructive pulmonary disease,
pneumonia and family history of cancer,2,3 and a number
of algorithms have been suggested including the Liverpool
Lung Cancer Risk Model.12 However, sensitivity analyses
carried out on the CAPER data, but not shown here, dem-
onstrate that neither smoking nor age impact on SLT.
The SLT distribution6 is the critical information
required to inform policies on investigational strategies.
We defined SLT as the time between symptoms attribut-
able to cancer and clinical diagnosis if no action is taken.
One contribution of this paper is that it shows how to esti-
mate SLT from case-control data, taking into account the
fact that GPs already order CXR following symptoms.
Exclusion of symptoms occurring in the last 3 months be-
fore diagnosis1,3,6 gives a more realistic impression of the
sensitivity of symptom criteria that would be obtained in
practice6 (see below), but removes a large proportion of
symptoms from the denominator, biasing lead times up-
wards. Further, in patients diagnosed because of symp-
toms, lead times associated with all symptoms, not just
those in the last 3 months, are censored and therefore
underestimated. Our approach was to estimate SLT both
including and excluding cases whose CXR finding of ‘sus-
pected lung cancer’ could have advanced the date of diag-
nosis, generating lower and upper estimates of SLT,
respectively, and taking the intermediate as our preferred
estimate. On this basis we estimated the mean SLT to be
5.3 months (95% CrI: 4.5–6.1) for lung cancer.
Information on the pre-diagnosis natural history of can-
cers centres on the mean sojourn time, that is the time
spent with detectable cancer pre-diagnosis. Negatively cor-
related estimates of mean sojourn time and test sensitivity
can be jointly derived from screening trials with two or
more screening rounds.13 Estimates of mean sojourn time
in lung cancer have ranged from 1.38 to 3.92 years.14–16
The latter estimate is to be preferred because it was accom-
panied by an estimated CXR sensitivity of 0.57, which ac-
cords closely with estimates from the National Lung
Screening Trial.17 More precise estimates of sojourn time
from this landmark trial are yet to be published.
The results presented here confirm that many sojourn
times are well in excess of 2 years, and provide a new,
complementary, perspective on the natural history of lung
cancer before diagnosis. A strength of the study was the in-
clusion of information on staging: although this was in-
complete, the stage distribution in the study was in good
agreement with the 9.4%, 4.7%, 20% and 61.9% in stages
Figure 4. Mean symptom lead time (SLT), ‘any two symptoms in 3
months’ by stage, including and excluding (Ex sus LC) cases with ‘sus-
pected lung cancer’ findings on CXR in the last 4 months. Average SLT
is intermediate.
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1,2,3, and 4, respectively, and missing, reported from the
two UK registries with the most complete stage data
2004–07.18
The main finding was that the majority of symptom
presentations in primary care occur in the last 6 months be-
fore diagnosis. SLT was largely independent of TNM stage
at diagnosis. This is a crucial finding as it suggests that pa-
tients diagnosed at stage 4 were not presenting with can-
cer-related symptoms at a higher rate while they were in
stage 1, otherwise longer SLTs would be associated with
later stage diagnosis. Instead, it seems that, regardless of
stage at diagnosis, the occurrence of most symptoms is late
and reflects an accelerating process during the final 3–6
months, leading eventually to diagnosis, whether as a re-
sult of GP-ordered investigation, accidental discovery by
other specialists or later presentation as an emergency.
Overlaid on this process, however, is a robust finding
that a small proportion of patients present with symptoms
associated with cancer much earlier. Diagnosis could there-
fore be advanced considerably, with a probable improved
staging at diagnosis, but only in a minority of cases: only
29% of all symptoms attributable to lung cancer occurred
more than 6 months before diagnosis, and 19% of cases
did not present these symptoms at all in the 2 years before
diagnosis.
The most serious limitation of the study is that observa-
tions only run to the 2 years before diagnosis, and may
therefore underestimate the SLT. However, if the rate of
symptom presentation 25–36 months before diagnosis is at
the same rate as that we observed in the 7–24 months, the
average lead time would rise from 5.3 to 8.3 months. Note
that these SLT estimates overestimate the lead time to start
of treatment. Another limitation is the small study size,
which prevents us extracting the more detailed information
on time between symptom presentations that would be
required to predict the performance of a sustained pro-
gramme of symptom-based investigation.
Implications for investigative strategies
We can compare the benefits of a programme of investiga-
tion based on symptoms presenting in primary care, with a
standard screening programme targeted at smokers. The
mean sojourn time, about 4 years for lung cancer, repre-
sents an upper bound on the lead time that can be obtained
from a standard screening programme. For common so-
journ time distributions, in a prevalent screen with a 100%
sensitive test, the expected lead time is at least one-half of
the mean sojourn time, in other words over 2 years. Recent
UK data suggest that 66% of lung cancers can be found in
the 31.3% most smoking-exposed population,3 giving an
expected lead time of at least 2 years for 66% of cancers
and zero for the remaining 34, an average of over 1.32
years.
We found that 81% of lung cancers met the symptom
criteria at least once, and 23% of controls did so.
However, the case-control design aligns the cancer cases so
they all present at their highest rate during the study. In a
symptom-based programme run over a random 2-year
period, in which patients were tested no more than once, a
far lower sensitivity would be obtained, and lower specifi-
city would be obtained if the programme ran for more
than 2 years.
Some 21% of the cases would be picked up serendip-
itously in the sense that their symptoms were not cancer-
related. The patients concerned then benefit from a
substantial lead time. However, this detracts from effi-
ciency and yield as it is equivalent to screening a propor-
tion of patients at random. Taking this into account, and
optimistically assuming symptoms would identify 81% of
cases, the mean lead time would be 0.62 years, or 0.78
years if cases present symptoms at a higher rate over a
36-month period before diagnosis. During a sustained pro-
gramme, whether symptom- or smoking-based, lead times
will be higher as cases will be detected earlier, but what-
ever interval is set between consecutive screens, lead times
Table 4. Stage distribution at diagnosis. Patients with and without a CXR finding of ‘suspected lung cancer’ in the CAPER study,
compared with routine data Eastern Region, UK, National Cancer Intelligence Network (NCIN), 2006-08; and with the National
Lung Screening Trial (NLST) 1st (prevalent) round19 and 2nd and 3rd (incident) screening rounds17
Study % Stage 1 % Stage 2 % Stage 3 % Stage 4, or missing Total cases (100%)
CAPER ‘Suspected LC’ on CXR 15.5 7.8 13.6 63.1 103
No ‘suspected LC’ on CXR 9.7 6.3 11.8 71.5 144
NCIN GP route of referral 14.7 6.5 29.4 59.4 3977
Other route of referral 9.3 3.5 23.2 63.9 5695
NLST Prevalent, CXR 46.5 8.3 25.6 22.7 136
Prevalent, CT 58.8 16.7 29.6 16.9 270
Incident, CXR 48.3 9.8 19.6 22.4 143
Incident, CT 64.6 7.4 14.8 13.2 379
LC, lung cancer; CT, computerized tomography.
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will be shorter in the symptom-based programme, as cases
will have met symptom criteria before they are investi-
gated, which occurs relatively late.
These pessimistic conclusions about lead times in symp-
tom-based vs smoking-based strategies are supported by
data on the distribution of stage at diagnosis. Table 4
shows a useful, but modest increase in the proportion of
stage 1 diagnoses in patients receiving a ‘suspected lung
cancer’ finding on CXR in the CAPER study, very similar
to unpublished data on route of diagnosis from the
National Cancer Intelligence Network. However, the ex-
tent of the shift towards stage 1 due to symptom-based
diagnosis in primary care is dwarfed (Table 4) by what has
been achieved in the National Lung Screening Trial.17,19
However, a full evaluation would need to take account of
the over-diagnosis in lung cancer screening.20,21
Lung cancer is unusual in that screening can be targeted
on a relatively sensitive and specific marker, smoking. In
other cancers a symptom-based strategy based on sensitive
and specific criteria could be effective, and cost-effective,
compared with no intervention, or as an adjunct to screen-
ing. However, a recent study of ovarian cancer, to our
knowledge the only other study discussing SLT, concluded
that a symptom-based programme could advance diagnosis
by no more than 3 months.6
Patients presenting in primary care require diagnosis
and treatment, and guidance on criteria for investigation is
required. However, whether increased symptom-based in-
vestigation can lead to better cancer outcomes can only be
assessed by study of the SLT distribution, based on ana-
lyses of large-scale case-control studies, looking at primary
care data over a long period before diagnosis.
Supplementary Data
Supplementary data are available at IJE online.
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